Ani Pharmaceuticals (ANIP) Restructuring Costs (2022 - 2023)
Ani Pharmaceuticals' (ANIP) quarterly Restructuring Costs came in at $2000.0 in Q2 2023, down 99.92% year-on-year from $2.6 million in Q2 2022, and down 99.82% quarter-over-quarter from $1.1 million in Q1 2023.
Ani Pharmaceuticals (ANIP) Restructuring Costs (2022 - 2023) Analysis & Trends
Ani Pharmaceuticals has disclosed Restructuring Costs across 2 years of filings, most recently posting $2000.0 for Q2 2023.
- Restructuring Costs for Q2 2023 came in at $2000.0, down 99.92% year-over-year; the trailing twelve-month figure through Mar 2024 was $2000.0 (down 99.97% YoY), and the FY2023 annual result was $1.1 million, down 80.07% from the prior year.
- Restructuring Costs came in at $2000.0 for Q2 2023 at Ani Pharmaceuticals, down from $1.1 million in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $2.6 million in Q2 2022 to a low of $2000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn |
| 10 | Ani Pharmaceuticals | 1.68 Bn | 1.37 Bn | 143.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 2,000.00 |
| Mar 31, 2023 | 1.13 Mn |
| Dec 31, 2022 | 1.20 Mn |
| Sep 30, 2022 | 1.54 Mn |
| Jun 30, 2022 | 2.57 Mn |